Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Wyeth

Status and phase

Completed

Phase 3

Conditions

Panic Disorders

Treatments

Drug: VENLAFAXINE

Drug: Paroxetine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00195598

0600B-101359

Details and patient eligibility

About

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Enrollment

70 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
Provide a written informed consent

Exclusion criteria

Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
Psychopharmacologic drugs within 14 days of study day 1